Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated promising efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to BTK inhibition, the phase I/II BRUIN study showed. Among 247 patients who had previously received a covalent BTK inhibitor, 73.3% (95% CI 67.3-78.7) achieved an overall […]
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor led to better oncologic outcomes compared with ibrutinib (Imbruvica) for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), according to an interim analysis of the phase III ALPINE study. Over a median follow-up of 15 months, the overall response rate — the primary […]